Safety, Tolerability and Pharmacokinetics of the New Formulation SHR-1316 in Subjects With Advanced Tumors
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of the new formulation SHR-1316 in subjects with advanced tumors.
Tumor
DRUG: SHR-1316
The incidence and severity of adverse events/serious adverse events (based on NCI-CTC AE 5.0), approximately 1 year|Maximum plasma concentration (Cmax), approximately 1 year|Time to maximum concentration (Tmax), approximately 1 year|Area under the concentration-time curve from time zero to time（AUC0-t）, approximately 1 year|Area under the concentration-time curve extrapolated to infinity (AUC0-∞.), approximately 1 year|Elimination half-life (t1/2), approximately 1 year|Clearance (CL), approximately 1 year|Volume of distribution (Vz), approximately 1 year|Trough concentration (Cmin), approximately 1 year|Accumulatio of ratio (Rac), approximately 1 year
Immunogenicity of SHR-1316, Anti-SHR-1316 antibody (ADA), neutralizing antibody (Nab), approximately 1 year|Objective response rate (ORR), approximately 1 year|Progression-free survival (PFS), approximately 1 year|Duration of response (DoR), approximately 1 year|Disease control rate (DCR), approximately 1 year|Overall survival (OS), approximately 1 year
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of the new formulation SHR-1316 in subjects with advanced tumors.